XORTX Therapeutics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 2.16 million compared to USD 7.72 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 5.22 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.6 CAD | -11.55% | -11.55% | +24.14% |
Apr. 22 | XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal | MT |
Apr. 08 | XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.14% | 8.62M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- XRTX Stock
- News XORTX Therapeutics Inc.
- XORTX Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023